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Heart Failure is a chronic cardiac condition that results in the heart being unable to pump the required 
amount of blood to meet the body’s metabolic needs. Its severity, multimorbidity and polypharmacy 
are all associated with short-term hospital readmissions, although it is unknown which is the strongest 
factor.  
Methods 
A prospective cohort study enrolled elderly Chronic Heart Failure patients from a single tertiary care 
hospital. Clinical, pharmacological, psychological, and demographic data were collected, while 
numerous assessments were tested discharge medications. Univariate and multivariate analyses were 
conducted to determine factors that were associated with hospital readmissions, both independently and 
in the presence of other factors. 
Results 
Of 56 participants, 55.4% were readmitted throughout the study period and 28.6% of readmissions 
occurred within 30 days. 96% of patients suffered from polypharmacy, although scores for Beers Drugs 
criteria, Drug Burden Index and Anticholinergic Risk Scale were low. Aspects of pharmacology, such 
as the number of different medications prescribed and the number of high-risk drugs present, provided 
significant results in univariate analyses, however, no aspects of patient medication significantly 
influenced hospital readmission in multivariate analyses.  
Results 
The population was heavily biased towards polypharmacy. Despite polypharmacy being highly 
prevalent, patient medications appeared to be appropriately prescribed. While some patients of patient 
medication may have influenced short-term hospital readmissions when analysed independently, they 
did not influence hospital readmission in the presence of other factors. Further research is required with 
more balanced study groups to accurately assess the effects of polypharmacy on Chronic Heart Failure 
populations’ hospital readmission.  
Word Count: 248 words  
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Assessment of Factors Affecting Hospital Readmission in 
Inpatients with Chronic Heart Failure 
Introduction 
As Australian society continues to develop, its population will continue to age. While this increased life 
expectancy allows for a better quality of life for more extended periods, it also leaves elderly Australians 
more prone to suffering from chronic disease. One such condition elderly Australians tend to suffer 
from compared to their youthful counterparts includes Chronic Heart Failure (CHF), a cardiac condition 
that ultimately results in the heart being unable to pump the required amount of blood to meet one’s 
metabolic needs. Self-reports from the Australian Bureau of Statistics estimate that 104,900 people aged 
18 and over suffer from CHF, about two-thirds of which were adults aged 65 and over1. While this 
statistic may seem small, it is essential to note that this it may underrepresent the actual proportion of 
Australians suffering from CHF, as some people may be unaware of their condition or unable to 
diagnose it properly2. 
Australians suffering from CHF also tend to suffer from several other chronic conditions, or 
comorbidities, resulting in what known as multimorbidity. European surveys suggest that up to 74% of 
CHF patients suffer from at least one comorbidity and that up to 43% suffer from two or more 
comorbidities3. Some of these comorbidities are directly linked to CHF, while others are associated 
with the aging process. Chronic Renal Failure, for instance, is directly linked to CHF as it results in the 
kidneys oversecreting renin, a renal marker responsible initiating the Renin-Angiotensin-Aldosterone 
(RAAS) System which in turn elevates blood pressure and cardiac output. Abusing the RAAS System 
to compensate for renal insufficiency results in the heart being unable to maintain an elevated workload, 
and with that weakens the cardiac muscle in the heart to cause CHF. Consequently, CHF leads to 
reduced blood reaching the kidneys, reinitiating the RAAS system and exacerbating both conditions in 
what is known as Cardiorenal Syndrome4. Comorbidities such as Chronic Obstructive Pulmonary 
Disorder (COPD), on the other hand, are often the result of lifestyle habits such as smoking but still 
contribute towards the development and exacerbation of CHF. As lung tissue degrades in COPD and 
oxygen absorption reduces, the respiratory system forces arterial pressure in the pulmonary arteries to 
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rise, resulting in pulmonary hypertension. This increase in pressure places excessive strain on the right 
ventricle on the heart as it pumps blood to the lungs, resulting in the cardiac muscle weakening and 
causing right-sided heart failure. Right-sided heart failure increases the workload of the left ventricle, 
ultimately resulting in left-sided heart failure5.  
Elderly CHF patients that also suffer from multimorbidity also tend to suffer from polypharmacy. While 
the scientific community is yet to decide on the concrete definition of polypharmacy, scientific literature 
often describes it as the concurrent use of five or more prescription medications6, 7. American studies 
show that 52% of CHF patients over the age of 75 suffer from polypharmacy, and French studies suggest 
that the number of different prescription medications given to CHF patients increases from 4.8 to 6.4 
after being hospital discharge8, 9, 10. It is important to note that some of these medications may bear 
anticholinergic or sedative risks. While tolerable in younger populations, elderly patients are more 
susceptible to the adverse side effects associated with anticholinergic and sedative medications. 
Anticholinergics function by blocking muscarinic receptors on nerve endings, acting as competitive 
inhibitors to acetylcholine (ACh), while sedatives work by increasing Gamma-Aminobutyric Acid 
(GABA) release in the Central Nervous System11. Despite having their benefits in conditions such as 
COPD or anxiety, anticholinergic and sedative medications can negatively impact elderly patients if 
misused. These can range from mild inconveniences such as dry mouth or dizziness to severe conditions 
such as dementia or hypothermia, decreasing quality of life12. Estimates suggest that up to 25% of CHF 
patients suffer from adverse reactions to anticholinergic or sedative at any capacity; an unnecessary 
burden for already ill people13.  
CHF patients are readmitted into hospital at excessively high rates. Australian studies show that 
between 25 – 30 % of all CHF patients are either readmitted into hospital or die within 30 days of initial 
hospital discharge, compared to the national average of approximately 15% for all hospital 
readmissions14, 15.  These rates are exceptionally high when comparing CHF as a condition to other 
chronic diseases such as cardiovascular disease (14.7) and stroke (6.4%) and cardiovascular disease 
(1.7%)16, 17. Abnormally high readmissions into hospital and other adverse short-term events place 
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financial and logistical strain on the healthcare system, costing it approximately $2B per year within 
the next ten years18. 
It is known that CHF is associated with exceptionally high short-term readmission rates and that 
multimorbidity and polypharmacy are also associated with high readmission risk and thus influence 
short-term hospital readmissions19. It is unknown, however, whether these factors independently 
influence short-term readmissions or do so as the result of the other factor. The effects of mental health 
such as depression and anxiety are also unknown and have the potential to impact a CHF patient’s 
ability to adhere to treatment regimens, and with that, increase the likelihood of hospital readmission if 
unable to do so. As a result, this research study will examine the factors that most strongly influence 
short-term hospital readmissions and other adverse outcomes in CHF patients. 
Polypharmacy is a strong indicator of short-term hospital readmission for other chronic conditions. 
Picker et al.’s 2015 study in assessing polypharmacy as an indicator of short-term hospital readmission 
in all inpatients found a significant and independent association between six or more different 
prescription medication and short-term hospital readmission (Odds ratio = 1.3, 95% Confidence 
Interval, 1.2 – 1.4, p = 0.003) and a significant association between an increase in prescription 
medication upon discharge and short-term hospital readmission20. Thus, it is hypothesised that 
polypharmacy is the strongest factor regarding short-term hospital readmissions for CHF patients in 
comparison to other variables such as physical and social factors. This study will attempt to holistically 
review pharmacological, social, psychological, and physical factors in inpatients suffering from CHF 
in order to:  
• Assess readmission within 30 days. 
• Assess potentially inappropriate medication within the study population.  
• To identify possible variables that are constant in individuals with poor short-term outcomes 
in an attempt to target patients with these variables for future interventions.  
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The study was conducted at the Royal Adelaide Hospital (RAH), a tertiary referral metropolitan hospital 
with approximately 700 beds. The research team prospectively enrolled participants throughout March 
– July 2020, as well as data gathered from CHF patients in 2019. Their population of interest comprised 
of inpatients aged 50 or older suffering from CHF, which was defined as either their reason of admission 
into the RAH, suffered from CHF at the time of admission or use prescription medications exclusive to 
CHF patients, such as Bisoprolol. Other inclusion criteria included the ability to provide either written 
or verbal informed consent, have sufficient English language skills to answer study questions and 
comply with study procedures. Patients were excluded if they were discharged to high-level residential 
aged care, had palliative intent or cognitive impairment which would interfere with providing informed 
consent and study assessments, or those whose clinical team felt would otherwise be inappropriate for 
the study. The research team used Allscripts Sunrise Electronic Health Record (Allscripts, Chicago, IL) 
to filter inpatients to only display those who explicitly suffer from CHF, or use medications prescribed 
exclusively for CHF patients (e.g., bisoprolol). Medical records were checked for age, to confirm 
disease diagnosis and to review residential status. Clinical staff on hospital wards were also approached 
to confirm patient eligibility. Once deemed as appropriate for the study, the research team then directly 
approached patients, informed them about the study and invited them to participate. Figure 1 provides 
a flowchart of the number of participants involved at each stage of the study.  
Data Collection 
Once the patient provided informed consent, the research team collected data through the following 
assessments. Participants were asked about the number of general practitioners, specialists and 
pharmacies they had seen in the last twelve months, whether they had received Chronic Disease Care 
Plans or Home Medicines Review and asked about their living situations. Hilmer et al.’s modified 
Reported Edmonton Frail Scale was used to assess frailty alongside the Clinical Frailty Scale and 
Barthel’s Index to gain an understanding of the participants’ general health21. Emotional wellbeing was 
measured through the 21-item Depression Anxiety and Stress Scales (DASS-21), while the 
Multidimensional Health Locus of control was used to measure the factors that participants believed 
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controlled their health22, 23. Comorbidities and medications were collected from participant’s case notes 
or their Electronic Medical Record. Blood test results, final discharge dates and subsequent 
readmissions were gathered from Open Architecture Clinical Information System (OACIS) v 7.1.0.106 
(OACIS, Telus Health, Longueil, Canada). In the event that participants were discharged before 
baseline data collection was completed, any remaining assessments were either sent in the mail or 
completed over the phone. It is also important to note that some participants were unable to complete 
the cognitive component of the Reported Edmonton Frailty test due to several reasons, and thus were 
not asked to undertake it. When analysing the data, participants who were unable to complete the 
cognition component of the test were excluded when analysing Reported Edmonton Frailty Test data.  
Assessment of Medications 
The research team counted the total number of regular discharge medicines and administrations per day 
from either the patient’s discharge summary or case notes. It is important to note, however, that 
medications that were taken as required or prescribed for short periods were excluded from their count. 
Polypharmacy was defined as the use of five or more regular medications, while hyperpolypharmacy 
was defined as the use of ten or more regular medications as agreed upon in the general scientific 
community24, 25. The 2015 and 2019 American Geriatrics Society Beers Criteria for Potentially 
Inappropriate Medication Use in Older Adults were used to assess the appropriateness of patient 
medications26, 27. These two criteria were used alongside the Drug Burden Index and the Anticholinergic 
Risk Scale to assess for anticholinergic and sedative burden28, 29, 30, 31. The research team used these 
different criteria to analyse participant medications for further analysis comprehensively.  
Measurement of Outcomes 
Time to readmission was the primary outcome measured. The research team used OACIS to determine 
when participants were readmitted into hospital, including all unplanned readmissions. Emergency 
department (ED) admissions were also included in this count and were not recounted if a patient was 
transferred into a ward and then reappeared in ED. Secondary outcomes included readmission within 
30 days. Date of death, when applicable, was sourced from OACIS. Patients who were lost to follow 
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up had their censor dates recorded as their last form of contact, including follow up assessments or 
outpatient appointments at the Royal Adelaide Hospital.  
Statistical Analysis 
The research team used SPSS version 26 (IBM Corp, Armonk NY, USA) to analyse its data. Firstly, 
the non-parametric one-sample Kolmogorov-Smirnov test was used to determine if scale data were 
normally distributed or not. At this point, scale data not normally distributed were analysed by the 
independent samples T-test while normally distributed scale data was analysed using non-parametric 
independent samples Mann-Whitney U test. Kaplan-Meier analyses were used to conduct univariate 
survival analyses of time to readmission. Significant or near significant results from the Kaplan-Meier 
analyses (i.e. P <0.2) were used in a Cox Regression multivariate analysis for time to readmission. 
Variables possessing the great p-value were removed from the analysis until a final model, with all 
variables producing p values of < 0.05, was produced. Polypharmacy and other aspects of participant 
medications were then integrated into this model to determine how powerful an influence they are on 
participant readmissions in comparison to the already-present variables. When using scale data such as 
BMI or the number of different medications prescribed to analyse time to readmission in univariate and 
multivariate analyses, it was categorised to analyse it in a simple manner while also comparing distinct 
groups of participants. For instance, BMI was categorised into differing weight ranges such as 
underweight, healthy weight, overweight and obese, while the number of different prescription 
medications was categorised to compare individuals with more than fifteen medications to those with 
less than fifteen medications. 
Ethical Considerations 
This study was approved by the Central Adelaide Local Health Network Human Research Ethics 
Committee (reference number: R20190301). All participants gave written or verbal informed consent 
and were given a copy of their consent form. 
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Eligible and approached 
N = 87 
Declined to participate 
N = 29 
Consented 
N = 58 
Excluded after consent 
N = 2 





N = 7 
(Withdrew from follow 
up questionnaires [1]) 
Lost to follow up [6]) 
Analysed 
N = 56 
Figure 1: A CONSORT diagram showing the recruitment process of the study 
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Results 
Fifty-eight participants were enrolled in the study, with 56 having results analysed following 
the exclusion of two participants. 55.4% of participants were readmitted throughout the study, 
and 28.4% of all participants were readmitted into hospital within 30 days of initial discharge. 
The participants were predominantly male, and the mean age of the cohort was 69.7 years (± 
9.2, 51 – 91). Further demographic and clinical information is available in Table 1. 
Table 1: Demographic and clinical traits of the study cohort. 
 
 Statistics (N=56) 
Age at Consent (Years) 69.7 ± 9.2, 51– 91 
Weight at Consent (Kg) 92.8 ± 23.9, 45 – 162  
Height at Consent (Cm)  170.0 ± 9.1, 152 - 186 
Body Mass Index (BMI)  32.16 ± 8.45, 15.57 – 53.83 
Gender (Male) 36 (64.3%) 
Country of Birth (Born In Australia) 39 (69.6%) 
Living Situation (With Someone Else) 26 (46.4%) 
Rural Residency 14 (25%) 
  









Readmitted After Discharge 31 (55.4%) 
Readmission Within 30 Days 16 (28.6%) 
Total Comorbidities 7, 5 – 9  
Diabetes 46 (82.1%) 
Hypertension 39 (69.6%) 
Ischaemic Heart Disease 34 (60.7%) 
Hypercholesterolemia 32 (57.1%) 
Atrial Fibrillation 27 (48.2%) 
Chronic Renal Failure 18 (32.1%) 
Depression  14 (25.0%) 
Chronic Obstructive Pulmonary Disease 13 (23.2%) 
Anaemia 13 (32.1%) 
  
Hba1c (Mol/L) 7.9 ± 1.8, 5 – 11.9 
Creatinine (Mol/L) 1.6 ± 0.7, 0.2 – 3.3 
Haemoglobin (Mg/Dl) 107.5, 99 – 137.8 
Low-Density-Lipoprotein (Mol/L) 1.6 ± 0.7, 0.2 – 3.3 
High-Density-Lipoprotein (Mol/L) 0.9, 0.7 – 1.3 
Estimated Glomerular Filtration Rate (mL)  47.5, 32.3 – 69.5 
Creatinine Clearance (mL) 72.4 ± 45.5, 17.1 – 213.2 
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Table 2 summarises patient medications. Patients, on average, were prescribed 11.1 different 
medications upon hospital discharge. 54 (96.4%) patients suffered from polypharmacy, while 
35 (62.5%) of patients suffer from hyperpolypharmacy, which is generally described as the use 
of 10 or more prescription medications. The 2015 and 2019 Beers Drugs Criteria scores were 
both low (median = 0.0, IQR = 0.0 – 1.0), as were Drug Burden Index scores (median 0.4, IQR 
0.0 – 0.7). The cohort also displayed a median score of 0 on the Anticholinergic Risk Scale 
(IQR 0 – 0). Despite these numbers, the median number of Drug-Drug Interactions was 1 (IQR 
0 – 2).  
 








 STATISTICS (N=56) 
Number of Different Medications Upon 
Discharge 
11.1 ± 4.2, 3.0 – 22.0 
Number of Administrations Per Day 14.6 ± 6.3, 4.0 – 31.0 
Polypharmacy 54 (96.4%) 
Hyperpolypharmacy 35 (62.5%) 
Acetylcholine Risk Scale Score 0.00, 0.00 – 0.00 
Drug Burden Index Score 0.42, 0.00 – 0.67 
Number of Beers 2019 Drugs 0.0, 0.0 – 1.0 
Number of Beers 2015 Drugs 0.0, 0.0 – 1.0 
Drug Burden Index Score 0.4, 0.0 – 0.7 
Total Number of High-Risk Drugs 1.0, 0.0 – 2.0 
Duplicate Drugs 0.0, 0.0 – 0.0 
Sedative Drugs 0.0, 0.0 – 0.0 
Anticholinergic Drugs 0.0, 0.0 – 0.0 
Drug-Drug Interactions 1.0, 0.0 – 2.0 
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The results from the frailty tests conducted and psychological tests such as the DASS-21, are 
summarised in table 3. 51 participants completed the cognition component of the Edmonton 
Frail Scale; thus, only the total score with 51 participants is recorded. Findings from the 
Edmonton Frail Scale are categorised according to the classification from Hilmer et al.’s 
version of the frailty test. Barthel’s Index scores were categorised in increments from ten, 
starting from seventy. Clinical Frailty scores were classified in increments of one, starting from 
three, while Barthel’s Index scores were classified in increments of ten, starting from seventy. 
DASS-21 and Locus of Control scores were not categorised in any particular manner. 
   
Shareef Zahr Honours Thesis a1725595 
Page 14 of 29 
 




 STATISTICS (N=56) 
Edmonton Frailty Test: 
• Not Frail (0 – 5) 
• Vulnerable (6 – 7) 
• Mildly Frail (8 – 9) 
• Moderately Frail (10 – 11) 
• Severely Frail (12+) 
 





Edmonton Frailty Test (Without Cognition) 
• Not Frail (0 – 5) 
• Vulnerable (6 – 7) 
• Mildly Frail (8 – 9) 
• Moderately Frail (10 – 11) 








Barthel Index (N=55): 
• <70 
• 70 – 80 







Clinical Frailty Score (N=55): 
• =<3 (Not Frail) 
• 4 (Mildly Frail) 
• 5 (Moderately Frail) 





 8 (14.50%) 
Dass-21 Depression Subscale 4.00, 2.00 – 10.00 
Dass-21 Anxiety Subscale 5.00, 3.00 – 11.00 
Dass-21 Stress Subscale 6.00, 2.00 – 9.50 
Locus of Control (Internal) 24.00, 20.00 – 26.25 
Locus of Control (Chance) 17.26 ± 7.57, 6.00 – 32.00 
Locus of Control (Powerful Others) 23.12 ± 6.60, 7.00 – 36.00 
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Kaplan-Meier survival functions were used to provide the probability of an object of interest; 
in this instance, participants enrolled in the study encountering an event within a certain time 
frame. In this study, the event was hospital readmission at any time during the study period. It 
is important to note that Kaplan-Meier survival functions are a univariate analysis, meaning 
that they only assess one variable at any given instance.  
The Kaplan-Meier survival functions generated showed that numerous variables were 
significantly associated with hospital readmissions when analysed independently. These 
variables include the total score of the Reported Edmonton Frailty Test, reported number of 
the falls in the last 12 months, Clinical Frailty scores, BMI, and the presence of hypertension. 
They also provided near-significant results (p > 0.2) for variables regarding hospital 
readmissions. Aspects of patient medications such as the number of different medications taken 
and Drug Burden Index scores were near significant, as well as comorbidities such as asthma 
and osteoarthritis. Despite some data showing significant or near-significant results, such as 
Acetylcholine Risk Scale score and Left Ventricular Ejection Fraction, there was no 
identifiable relationship between the variable and hospital readmissions. Thus, they were 
deemed biologically implausible and excluded from the Cox-Regression multivariate analysis. 
A comprehensive table detailing the relationships between hospital readmission and the data 
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Table 4 shows the final model generated by the Cox-Regression analysis. Factors pertaining to 
polypharmacy and other aspects of patient medications were then assessed against the shown 
variables to determine if polypharmacy significantly contributed to hospital readmission in the 
presence of other variables. No aspects of patient medication, including polypharmacy, 
significantly contributed towards hospital readmissions in the presence of other variables.  
 

















Falls 12 months 1.6 0.55 0.003 5.1 1.8 15.0 
Hypertension 2.2 0.89 0.015 8.7 1.5 49.4 
Asthma 2.8 0.88 0.002 16.0 2.8 90.0 
Osteoarthritis 2.6 0.94 0.006 13.1 2.1 83.0 
Hypercholesterolemia 1.4 0.68 0.041 4.0 1.1 15.2 
Reported Edmonton 
Frailty Test (Total) 
0.29 0.089 0.001 1.3 1.1 1.6 
BMI -0.069 0.029 0.017 0.93 0.88 0.98 
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Discussion 
Over half the study cohort was readmitted into hospital throughout the study period, with 30% 
of all participants readmitted within 30 days. The study group was predominantly male, with 
the average age of participants being close to seventy years old. The cohort was also generally 
overweight, if not obese, and typically suffered between five to nine comorbidities. The 
majority of the cohort suffered from diabetes (82.1%), hypertension (69.6%), ischaemic heart 
disease (60.7%), hypercholesterolemia (57.1%), and atrial fibrillation (48.2%). However, 
conditions such as anaemia and COPD were not as frequently reported (32.1% and 23.3% 
respectively) relative to the comorbidities mentioned above. These findings are somewhat 
consistent with what is known in the literature. While most CHF patients typically suffer from 
atrial fibrillation, ischaemic heart disease and hypertension, non-cardiovascular diseases such 
as chronic renal disease were also apparent in other study cohorts32, 33. Diabetes was heavily 
over-represented, as other heart failure study cohorts typically have 25% of participants have 
diabetes34. The discrepancies in these statistics may be due to the small sample size of this 
study’s cohort, as only 56 sets of data were gathered by the end of the study period in 
comparison to other studies that typically comprise of thousands of participants.   
Over 96% of the participants suffered from polypharmacy. Other studies typically show that at 
least 50% of CHF patients suffer from polypharmacy in some capacity, with even less suffering 
from hyperpolypharmacy. Australian studies focusing on polypharmacy in all patients report 
that 36.1% and 43.3% of Australians aged ≥70 and ≥50 respectively suffer from 
polypharmacy35. It is important to note, however, that there is limited information regarding 
the presence of polypharmacy in Australian CHF inpatients. By averaging 11.1 different 
medications, the study cohort also uses more medication than cohorts in other CHF studies, 
which have been found to use up to 6.8 different medications36. The number of medications is 
typically an indicator of health outcomes as using a higher number of different medications 
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increases the likelihood of drug-drug interactions and inappropriately prescribed medications 
being used. In saying that, this study cohort displayed low scores for both the 2015 and 2019 
Beers Criteria, Drug Burden Index and Anticholinergic Risk Scales, implying that their 
medications were appropriately prescribed.  These findings may be due to heart failure patients 
suffering from multiple comorbidities; thus, medical professions may prepare more carefully 
thought out treatment regimens to ensure that medications intended for heart failure do not 
negatively affect the outcome of a given comorbidity.  
The univariate analyses suggest that the number of different GP practices and pharmacies 
participants visit, Reported Edmonton Frailty Test and Clinical Frailty scores, the number of 
falls in the last twelve months and BMI all significantly contribute towards hospital 
readmission when analysed independently. Anticholinergic Risk Score, Beers Drug Scores and 
Conflicting Treatment scores also significantly contributed towards hospital readmission when 
analysed independently, despite generally being low for the cohort. It is important to note, 
however, that the Anticholinergic Risk Score, Beers Drug Scores, Conflicting Treatment score 
and the number of different GP practices visited were all not biologically plausible. They did 
not correspond to trends set in the scientific literature and therefore, were not considered 
appropriate factors to influence short-term hospital readmissions independently36,37. BMI and 
Reported Edmonton Frailty Test Scores both provided significant values and were biologically 
plausible, thus in this study cohort can be considered factors that influenced hospital 
readmissions in a vacuum.  
After removing all statistically insignificant variables, the multivariate analysis showed that 
the number of falls in the last twelve months, hypertension, asthma, osteoarthritis, 
hypercholesterolemia, Reported Edmonton Frailty Score and BMI all significantly contributed 
towards hospital readmission in the presence of other factors, with other studies reporting that 
the odds of readmission increase by 1.12 percent per point scored in the Reported Edmonton 
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Frailty Test. These findings are mostly consistent with that is known in the literature, for 
instance, hypertension and hypercholesterolemia are risk factors for CHF32 while reporting a 
high number of falls in the last twelve months or high scores on the Reported Edmonton Frailty 
test indicate that increased frailty results in increased hospital readmissions, a finding present 
in all ill people38. It was noted that the hazard ratio for BMI was < 1, indicating an inverse 
relationship between BMI and hospital readmission. While this relationship initially seems 
biologically implausible, scientific literature suggests that it may be due to the Obesity Paradox, 
which suggests that increased BMI are independently associated with a lower risk of death and 
death due to worsening Heart Failure39. In the multivariate model, no aspects of polypharmacy 
or patient medications showed significant or near-significant results, despite univariate 
analyses suggesting otherwise. 
The lack of significant findings for polypharmacy and patient medications in the multivariate 
analysis may be due to the study cohort’s small sample size, the demographics of the study 
cohort and the screening requirements to partake in the study. The study cohort only comprised 
of 56 participants by the end of the study period, 54 of which suffered from polypharmacy. 
This means that the non-polypharmacy group only consists of two participants, which is an 
insufficient number when being examined as the strongest indicator of hospital readmission. 
While it can be argued that small sample sizes may result in significant findings occurring 
through sheer coincidence, the final Cox-Regression model shows a number of factors that 
both biologically plausible and shown in other studies to significantly contribute towards 
hospital readmissions3, 10, 19, 32, 33. As a result, the number of participants enrolled in the study 
may not be accountable for the lack of significant findings regarding polypharmacy. It is also 
essential to consider that the majority of participants were sick, older adults who also tend to 
see medical professionals frequently40, and with that do not adequately reflect the situation of 
younger patients or those unable to contact healthcare services consistently.  
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As mentioned earlier, the number of different medications the study cohort had greatly 
exceeded those in similar studies7, 8, 19. While it is scientifically plausible to assume that the 
probability of hospital readmission is directly proportional to the number of different 
medications taken, as seen in the univariate analyses which display an association between 
these two variables, it is essential to consider how properly, or poorly, these drugs are 
prescribed and interact with each other. Patient medications, despite being high in quantity, 
treatment regimens were appropriately prescribed. Both 2019 and 2015 Beers Drugs Criteria 
scores had median scores of 0.0 (IQR 0.0 – 1.0), Drug-Drug Interaction score had a median 
score of 1.0 (IQR 0.0 – 2.0), and few high-risk drugs were prescribed to participants (median 
score of 1.0, IQR 0.0 – 2.0). Participants were at low risk of any anticholinergic risk (median 
score 0.0, IQR 0.0 – 0.0) and generally had low scores on the Drug Burden Index (median score 
0.42, 0.00 – 0.67). As medications were appropriate prescribed, it also meant unlike the 
presence of pharmacology, the number of participants scoring on these drug assessment criteria 
are generally low.  This was not applicable to some variables, such as the Drug Burden Index 
scores and total high-risk drugs, which had rather even groups and thus produced near-
significant results (p = 0.08 and 0.06 respectively). It is also important to note that despite some 
aspects of patient medication providing near significant results in the Kaplan-Meier analyses, 
the probability of hospital readmission was not directly nor inversely proportional to trends in 
the data. Acetylcholine Risk Scale scores, for instance, produced a p-value of 0.04, but when 
categorising the data to compare two distinct groups, the findings did not stay significant, in 
this instance the p-value for Acetylcholine Risk Scale score equalling 0.58 when comparing 
scores of zero to scores greater than zero.  
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The prospective design of the study is one of the strengths it possesses; however, small sample 
sizes and only one location to gather data impinge the ability to generalise findings. A more 
extensive study would allow for a greater sample size to be examined for a more extended 
period not only to gather more data regarding short-term hospital readmissions but potentially 
delve into the impacts each variable has on long-term hospital readmissions. Despite the length 
of time allocated for the study period, it was able to create a complex data set of a complicated 
group of inpatients which can thus be further analysed in future studies. With this in mind, it is 
essential to maintain compliance for assessments to allow for as much data to be collected as 
possible. 
It is important to note that the study design also had a number of flaws. One such shortcoming 
was failing to recruit enough participants to meaningfully contribute to the non-polypharmacy 
group. Pre-screening participants based on the number of different medicines they are 
prescribed may circumvent this issue. Thus, a study cohort that distributes polypharmacy and 
non-polypharmacy more evenly can be created to allow for sufficient data to be collated for 
both study groups. The vast majority of participants also lived in urban or suburban areas, and 
with that unable to properly reflect outcomes in rural or remote CHF patients. Readmission 
data collected from OACIS were only able to include data for public hospitals; thus, 
readmissions may have been missed if participants were readmitted in private hospitals. Older 
patients who are severely ill would tend to use more medications, which may explain the 
difference in numbers between the polypharmacy and non-polypharmacy groups. 
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Conclusion 
Polypharmacy was observed at a much higher rate in the study group than in Australia and 
other developed nations; however, medications were mostly prescribed appropriately. Keeping 
this in mind, polypharmacy and other patient factors displayed some association with hospital 
readmissions when analysed individually, however, did not significantly contribute towards 
hospital readmission in complex situations such as those in CHF patients. The research 
provides an insight into the factors that contributed towards hospital readmissions in the study 
group, such as aspects of frailty and comorbidities associated with CHF. Improving the study 
design by allowing for larger sample sizes and more evenly distributed cohorts between 
polypharmacy and non-polypharmacy groups may produce more meaningful results regarding 
polypharmacy and patient medications. 
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Appendix 





Number Of Different 
Medications 
3 categories: 
- < 10 medications 
- 10 – 14 medications 
- > 15 medications 
0.16 Using less than ten different medications led to a smaller probability of hospital 
readmission. In most instances, using fifteen or more different medications resulted in 
a higher probability of hospital readmission. The data was recategorized into two 
groups: participants that use less than fifteen different medications and those that use 
more than fifteen different medications.  
Number Of Different 
Medications 
2 categories: 
- < 15 medications 
- >= 15 medications 




Unchanged 0.04 The probability of hospital readmission in participants were neither directly nor 
inversely proportional to Acetylcholine Risk Scale scores. Thus, the data was 




- Scores of 0 
- Scores greater than 0 
0.58  
Drug Burden Index 
Score 
2 categories: 
- Scores of 0 
- Scores greater than 0 
0.08 A Drug Burden Index Score of zero resulted in a lower likelihood of hospital 
readmission in comparison to Drug Burden Index scores greater than zero.  
Reported Edmonton 
Frailty Scale (Total) 
unchanged 0.06 The probability of hospital readmission in participants were neither directly nor 
inversely proportional to the total Reported Edmonton Frailty score. Thus, the data 
was reassessed using the categories derived from Hilmer et al’s Reported Edmonton 
Frailty 
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Reported Edmonton 
Frailty Scale (Total) 
5 categories: 
- Not frail (0 – 5) 
- Vulnerable (6 – 7) 
- Mildly frail (8 – 9) 
- Moderately frail (10 – 
11) 
- Severely frail (12+) 
0.019 Participants that were recorded as ‘Not frail’ had the lowest probability of hospital 
readmission. The probability of hospital readmission was directly proportional to the 
frailty of the participant (i.e. severely frail participants had higher probability of 
hospital readmission than mildly frail participants).  
Reported Edmonton 
Frailty Scale (Total) 
3 categories: 
- Not frail (0 – 5) 
- Vulnerable (6 – 7) 
- Any frailty (8+) 
0.006 Participants that were recorded as ‘Not frail’ had the lowest probability of hospital 
readmission. Those that were reported to have ‘any frailty’ had the highest probability 
of hospital readmission.  
Falls (Last 12 Months) 2 categories: 
- No falls 
- Any falls 
0.033 Participants that were recorded as not having any falls in the last 12 months had lower 
probability of hospital readmission in comparison to those recorded as having any 
falls in the last 12 months. 
Body Mass Index categorised as usual according 
to BMI, i.e. 
- Underweight: BMI 
<18.5 
- Healthy Weight: BMI 
between 18.5 and 24.9 
- Overweight: BMI 
between 24.9 and 29.9 
- Obese: BMI between 
30 and 34.9 
- Morbidly Obese: BMI 
> 35 
0.017 Participants that were recorded as obese or morbidly obese had the lowest probability 
of hospital readmission. Patients that were considered underweight or overweight had 
the highest probability of hospital readmission. The data was reassessed using the 
following categories: Underweight (<18.5) and not underweight (>=18.5).  
Body Mass Index 2 categories: 
- Underweight (<18.5) 
- Not underweight 
(>=18.5) 
0.002 Participants recorded as being underweight had a higher probability of hospital 
readmission in comparison to those not recorded as being underweight.  
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Clinical Frailty 2 categories: 
- Not frail (i.e. 1 – 4) 
- Frail (i.e. 5+) 
0.024 Participants recorded as being frail had higher probability of hospital readmission 
than those recorded as not frail.  
Left Ventricular 
Ejection Fraction 
categorised according to 
dysfunction: 
- Severe (<30%) 
- Moderate (30 – 39%) 
- Mild (40 – 49%) 
- “Normal” (>50%) 
0.085 The probability of hospital readmission in participants were neither directly nor 
inversely proportional to left ventricular ejection fraction percentages.  
Hypertension  0.009 Participants suffering from hypertension had higher probability of hospital 
readmission than those that do not suffer from hypertension.  
Asthma  0.091 Participants suffering from asthma had a higher probability of hospital readmission 
than those not suffering from asthma.  
Osteoarthritis  0.094 Participants suffering from osteoarthritis had a higher probability of hospital 
readmission than those not suffering from osteoarthritis.  
Hypercholesterolemia  0.13 Participants suffering from hypercholesterolemia had a higher probability of hospital 
readmission than those not suffering from current solid tumours.  
Total Treatment 
Conflict 
unchanged 0.001 The probability of hospital readmission was neither directly nor inversely 
proportional to total treatment conflicts. Thus, the data was reassessed using two 






0.10 Participants with any conflicting treatments had higher probability of hospital 
readmission than those with zero conflicting treatments.  
Total High Risk unchanged 0.009 The probability of hospital readmission was neither directly nor inversely 
proportional to the total number of high-risk medications. Thus, data was reassessed 
using two categories: zero high-risk medications and more than zero high-risk 
medications  
Total High Risk 2 categories: 
- 0 
- >0 
0.061 Participants reported as using any high-risk medication had a higher probability of 
hospital readmission than those not reported as using any high-risk medications.  
Duplicate Drugs unchanged N/A No participants were recorded as having any duplicate drug; thus, the data could not 
be assessed.  
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unchanged 0.092 The probability of hospital readmission was neither directly nor inversely 
proportional to the total number of duplicate, sedative and anticholinergic drugs. 
Thus, the data was reassessed using two categories: zero of the aforementioned drugs 







0.18 Participants recorded as using any duplicate, sedative or anticholinergic drug had a 
higher probability of hospital readmission than those not using these drugs.   
2019 Beers Drugs unchanged 0.005 The probability of hospital readmission was neither directly nor inversely 
proportional to the 2019 Beers Drugs score. Thus, the data was reassessed using two 
categories: a score of zero and a score greater than zero.  




2015 Beers Drugs unchanged 0.004 The probability of hospital readmission was neither directly nor inversely 
proportional to the 2015 Beers Drugs score.  Thus, the data was reassessed using two 
categories: a score of zero and a score greater than zero. 
2015 Beers Drugs 2 categories: 
- 0  
- >0 
0.57  
